Abbott Presents Data on TriClip TEER System, Navitor TAVR System, and Amulet 360 LAA Occluder 

June 29, 2026—Abbott announced the presentation of the first United States real-world outcomes of the company’s TriClip transcatheter edge-to-edge repair (TEER) system for the treatment of tricuspid regurgitation (TR) and data on the company’s Navitor transcatheter aortic valve replacement (TAVR) system to treat aortic stenosis.

These datasets, which were delivered in late-breaking presentations at the New York Valves 2026 conference, reinforce the safety and effectiveness of the company’s devices in treating patients with heart valve disease, stated Abbott.

The company also advised that new results from the VERITAS study were presented for Abbott’s investigational Amulet 360 left atrial appendage (LAA) occluder, a next-generation device designed to reduce risk of stroke in patients with nonvalvular atrial fibrillation.

TriClip TEER System

According to Abbott, the TriClip presentation by Wayne Batchelor, MD, shared data from the TVT registry of 3,035 patients enrolled at 278 United States sites who underwent TriClip procedures.

As outlined by the company, key 30-day findings included the following:

• Significant TR reduction to moderate or less was achieved in 87% of patients.
• Patients had more than a 22-point improvement on average in the Kansas City Cardiomyopathy Questionnaire score.
• There were low rates of adverse events, including major bleeding (0.9%) and new permanent pacemaker (0.5%).

Navitor TAVR System

In the second presentation, Raviteja Reddy Guddeti, MD, discussed real-world outcomes from the STS/ACC Registry evaluating the use of Abbott's Navitor TAVR system to treat patients with small aortic annuli.

Abbott reported that the key 30-day outcomes from the Navitor presentation included the following:

• 98.2% of patients had mild or less paravalvular leak.
• A 7.5 mm Hg mean gradient indicated a low average pressure difference.
• Only 5.3% of patients experienced severe prosthesis-patient mismatch.

Amulet 360 LAA Occluder

Finally, Devi Nair, MD, presented a new analysis of 45-day data from the VERITAS study evaluating the safety, effectiveness, and procedural efficiency of the Amulet 360 device among 53 implanters participating in the study across the United States, Canada, and Europe.

Abbott noted that procedures were grouped among physicians’ experience levels: roll-ins (first procedure), early (between one to five procedures within analysis cohort), and experienced (more than five procedures).

As outlined by the company, the results from 458 total procedures performed at 34 sites demonstrated the following:

• 100% implant success after implanter’s fifth case.
• Complete closure (0 mm peridevice leak) in the majority of cases, from roll-ins (84.3%) to experienced (96.1%).
• Procedural efficiency improved with implanter experience.